{
    "id": 11339,
    "fullName": "STRN - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "STRN-ALK results from the fusion of STRN and ALK, and leads to constitutive activation of Alk, transforming ability in culture, and tumorigenicity in mice (PMID: 24613930). STRN-ALK fusions have been identified in thyroid, renal, colorectal, and lung cancer (PMID: 24613930, PMID: 26848800, PMID: 26933125, PMID: 29169525).",
            "references": [
                {
                    "id": 11170,
                    "pubMedId": 29169525,
                    "title": "Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A\u00a0Nonresponder to Alectinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29169525"
                },
                {
                    "id": 3596,
                    "pubMedId": 24613930,
                    "title": "Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24613930"
                },
                {
                    "id": 11169,
                    "pubMedId": 26848800,
                    "title": "Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26848800"
                },
                {
                    "id": 5443,
                    "pubMedId": 26933125,
                    "title": "Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26933125"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6801,
        "geneSymbol": "STRN",
        "terms": [
            "STRN",
            "PPP2R6A",
            "SG2NA",
            "STRN1"
        ]
    },
    "variant": "STRN - ALK",
    "createDate": "09/03/2015",
    "updateDate": "12/10/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11542,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) and Gemzar (gemcitabine) combination treatment resulted in decreased CA 19-9 level and tumor size in a pancreatic ductal adenocarcinoma patient harboring STRN-ALK (PMID: 28476735).",
            "molecularProfile": {
                "id": 11388,
                "profileName": "STRN - ALK"
            },
            "therapy": {
                "id": 6028,
                "therapyName": "Crizotinib + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13553,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Alecensa (alectinib) treatment initially resulted in tumor mass decrease in the lymph nodes of a patient with ALK-rearranged non-small cell lung cancer, but the disease progressed after 3 months and STRN-ALK was detected in pleural effusion (PMID: 29169525).",
            "molecularProfile": {
                "id": 11388,
                "profileName": "STRN - ALK"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11170,
                    "pubMedId": 29169525,
                    "title": "Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A\u00a0Nonresponder to Alectinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29169525"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6200,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Zykadia (ceritinib) treatment resulted in stable disease with a decrease in size in the tumor metastasis in a colorectal adenocarcinoma patient harboring a STRN-ALK fusion (PMID: 26933125).",
            "molecularProfile": {
                "id": 11388,
                "profileName": "STRN - ALK"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5443,
                    "pubMedId": 26933125,
                    "title": "Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26933125"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3559,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited cell proliferation of thyroid cells expressing STRN-ALK (PMID: 24613930).",
            "molecularProfile": {
                "id": 11388,
                "profileName": "STRN - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3596,
                    "pubMedId": 24613930,
                    "title": "Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24613930"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6201,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a colorectal adenocarcinoma patient harboring a STRN-ALK fusion demonstrated initial benefit with Zykadia (ceritinib) treatment, but became resistant after 9 months following the appearance of a KRAS G13D mutation (PMID: 26933125).",
            "molecularProfile": {
                "id": 22831,
                "profileName": "STRN - ALK KRAS G13D"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5443,
                    "pubMedId": 26933125,
                    "title": "Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26933125"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15132,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer initially responded to Tarceva (erlotinib), followed by Rociletinib (CO-1686), then Tagrisso (osimertinib) with partial response for 6 months, EGFR L747_A755delinsSRD and STRN-ALK were identified in post-progression tumor samples (PMID: 29883838).",
            "molecularProfile": {
                "id": 30778,
                "profileName": "STRN - ALK EGFR L747_A755delinsSRD"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19904,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with an advanced solid tumor developed resistance to treatment with Tarceva (erlotinib) and was found via cell free DNA testing to harbor EGFR T790M, an EGFR exon 19 deletion, STRN-ALK, and CCDC6-RET (PMID: 31300450).",
            "molecularProfile": {
                "id": 34664,
                "profileName": "CCDC6 - RET STRN - ALK EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17588,
                    "pubMedId": 31300450,
                    "title": "Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31300450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11388,
            "profileName": "STRN - ALK",
            "profileTreatmentApproaches": [
                {
                    "id": 6994,
                    "name": "ALK Inhibitor",
                    "profileName": "STRN - ALK"
                }
            ]
        },
        {
            "id": 22831,
            "profileName": "STRN - ALK KRAS G13D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30778,
            "profileName": "STRN - ALK EGFR L747_A755delinsSRD",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34664,
            "profileName": "CCDC6 - RET STRN - ALK EGFR exon 19 del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}